HOOKIPA Pharma: Q1 Earnings Insights

 

Shares of HOOKIPA Pharma HOOK fell 6.1% in pre-market trading after the company reported Q1 results.

Quarterly Results

Earnings per share fell 23.26% year over year to ($0.53), which were in line with the estimate of ($0.53).

Revenue of $5,301,000 rose by 43.43% from the same period last year, which beat the estimate of $3,970,000.

Looking Ahead

Earnings guidance hasn't been issued by the company for now.

HOOKIPA Pharma hasn't issued any revenue guidance for the time being.

Recent Stock Performance

Company's 52-week high was at $16.15

52-week low: $8.10

Price action over last quarter: Up 2.72%

Company Overview

HOOKIPA Pharma Inc is a clinical stage biopharmaceutical company developing a class of immunotherapeutics targeting infectious diseases and cancers based on its proprietary arenavirus platform that is designed to reprogram the body's immune system. It uses off-the-shelf technologies, VaxWave and TheraT, to elicit directly within patients a response of antigen-specific killer T cells and antibodies.

Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Date
ticker
name
Actual EPS
EPS Surprise
Actual Rev
Rev Surprise
Posted In: EarningsNewsBZI-Recaps
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!